tbuckley/cabot-search huggingface dataset:
Impact of timing of palliative care consults on disposition to type of hospice care.
Authors: Praneeth Baratam, Thomas Stiles Bemis, Dawn Seiders, Kristine Marie Ward, Michael Styler
Journal: Journal of Clinical Oncology (2019)

50 Background: The 2018 ASCO palliative care guidelines recommend palliative care team (PCT) involvement within 8 weeks for patients with an advanced cancer diagnosis. However, the optimal timing and impact of PCT consults on patient disposition in the inpatient setting has not been established. We investigated whether the timing of PCT involvement for in-patients with an advanced cancer diagnosis affected disposition to a home or inpatient hospice setting. Methods: We queried Hahnemann University Hospital’s Palliative Care In-patient database from 2016-2018 for patients with advanced cancer diagnosis, estimated life expectancy of &lt; 6 months, and recommendation for hospice. Dates of admission, initial PCT consult, discharge to an outpatient vs an inpatient hospice setting/in hospital death were examined. We then examined differences in hospice disposition and timing of PCT consults to determine the ideal consult time. Chi square analysis was used to determine differences in hospice disposition setting and timing of PCT consult. Results: We observed that 75% of PCT consults in our hospital are placed &lt;10 days of admission. We also found that a statistically significant higher percentage of patients were discharged to a home hospice setting (35.1%) when using a PCT consult time of &lt;10 days (p&lt;0.01). Only 17.5% were discharged home when PCT was consulted &gt;10 days after admission. We examined other cut-off times for consultation, but the difference in outcome was not statistically significant. Conclusions: Our findings show that a statistically significant higher percentage of patients went to a home hospice setting if PCT was consulted &lt;10 days of admission. This suggests that early PCT involvement can result in more patients being discharged to a home hospice setting and by extension improve the quality of end of life care for patients. We aim to implement criteria for appropriate timing of PCT consults at our institution and measure post implementation data with the goal of increasing the number of patients discharged to a home hospice setting. [Table: see text]
Abstract 525: <i>In vitro</i> Reverse Remodeling After Mechanical Unloading With Engineered Heart Tissue
Authors: Shi Shen, Lorenzo R Sewanan, Stuart G Campbell
Journal: Circulation Research (2019)

LVADs serve as a bridge to transplantation for many dilated cardiomyopathy (DCM) patients with advanced heart failure. In rare cases, mechanical unloading can lead to reverse myocardial remodeling sufficient for the removal of LVAD. We recreated the first reverse remodeling process in vitro in order to examine the role of active actin-myosin contraction and fibroblasts in contributing to this recovery, and to test the efficacy of drugs commonly prescribed for concurrent use with LVAD implantation. Engineered heart tissue (EHT) were prepared from decellularized porcine ventricular scaffolds in a proof-of-concept animal model with neonatal rat cardiomyocytes and subsequently with human induced pluripotent stem cell-derived cardiomyocytes and adult human cardiac fibroblasts. Mechanical stretch and myosin inhibition were used to simulate the pathological remodeling of DCM. Preliminary animal data showed that our model was able to capture the key features of DCM and reverse remodeling process including improved slack length, tissue stiffness, and active kinetics following mechanical unloading. β-adrenergic receptor response, protein assay, immunohistochemistry, and genetic analysis are being carried out to comprehensively investigate reverse remodeling in this artificial human system. Additional drug studies aim to investigate how reverse remodeling is affected by concurrent administration of β 1 antagonists and β 2 agonists (typical drug regimen for heart failure) and may inform new potential treatment during mechanical unloading to promote beneficial reverse remodeling for patients.
The Three E Proteins Define a Heterogeneity of the AML1-ETO-Containing Transcription Factor Complex (AETFC) and Differentially Regulate t(8;21) Leukemogenesis
Authors: Na Liu, Junhong Song, Yangyang Xie, Xiao-Lin Wang, Bowen Rong, Na Man, Meng-Meng Zhang, Qunling Zhang, Fei-Fei Gao, Mei-Rong Du, Ying Zhang, Jian Shen, Chun-Hui Xu, Cheng-Long Hu, Ji-Chuan Wu, Ping Liu, Yuan-Liang Zhang, Yin-Yin Xie, Ping Liu, Jinyan Huang, Qiu-Hua Huang, Fei Lan, Shuhong Shen, Stephen D. Nimer, Zhu Chen, Sai-Juan Chen, Robert G. Roeder, Lan Wang, Xiao-Jian Sun
Journal: Blood (2018)
EP1.09-09 Surgical Cases of Pulmonary Pleomorphic Carcinoma at Our Institution
Authors: H. Masuda, H. Arai, Y. Mishina, S. Nakamura, K. Shiino, K. Okudela, T. Iwasawa, M. Tajiri, M. Masuda
Journal: Journal of Thoracic Oncology (2019)
P1.01-76 Randomized Phase II Study of Immunotherapy With or Without Low Dose Chemotherapy for Patients with Performance Status of 2
Authors: T. Ahmed, J. Ruiz, T. Lycan, S. Addo, P. Gandhi, J. Miller, B. Levine, P. Triozzi, M. Bonomi, W.J. Petty
Journal: Journal of Thoracic Oncology (2019)
P2.04-61 Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity
Authors: R. Martin-Deleon, M. Sanchez, M. Benegas, C.M. Lucena, C. Cabrera, R. Reyes, D. Martinez, J. Ramirez, R.M. Marrades, N. Viñolas, C. Teixido, C. Agusti, N. Reguart, J. Sellares
Journal: Journal of Thoracic Oncology (2019)
Regulation of CXCR1, CXCR2 and CXCR4 in Human Neutrophils: Potential Role in the Release from the Bone Marrow, Clearance of Senescent Cells, and Cell Function at Sites of Inflammation.
Authors: Sedat Yildirim, Frank Bautz, Andreas M. Boehmler, Lothar Kanz, Robert Möhle
Journal: Blood (2005)
P2.12-23 Radiological Features of SCLC-Like and NSCLC-Like Large Cell Neuroendocrine Carcinoma (LCNEC)
Authors: B. Hermans, J. Derks, H. Gietema, E. Van Den Broek, E. Speel, A.M. Dingemans
Journal: Journal of Thoracic Oncology (2019)
P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
Authors: J. Van Meerbeeck, P. Van Schil, V. Surmont, R. Gaafar, R. Cornelissen, B. Hasan, A. Pochesci, A. Maat, P. Baas, F. Vermassen
Journal: Journal of Thoracic Oncology (2019)
Recurrent Genetic Variants of Long Non-Coding RNAs (lncRNAs) Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia
Authors: Dimitrios Papaioannou, Hatice Gulcin Ozer, Deedra Nicolet, Krzysztof Mrózek, Volinia Stefano, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Ann-Kathrin Eisfeld, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield
Journal: Blood (2017)
EP1.16-28 ALK Translocated Patients: Survival in an Unselected Population
Authors: B. Núñez-García, R. Gómez-Bravo, J.C. Sánchez, B. Cantos, M. Méndez, A.M. Morito, M. Blanco, V. Calvo, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
Authors: Jay Friedman, Ellen C. Moore, Paul Zolkind, Yvette Robbins, Paul E. Clavijo, Lilian Sun, Sarah Greene, Megan V. Morisada, Wojciech K. Mydlarz, Nicole Schmitt, James W. Hodge, Hans Schreiber, Carter Van Waes, Ravindra Uppaluri, Clint Allen
Journal: Clinical Cancer Research (2019)

Surgical resection of primary tumor with regional lymphadenectomy remains the treatment of choice for patients with advanced human papillomavirus-negative head and neck squamous cell carcinoma. However, even when pathologic disease-free margins can be achieved, locoregional and/or distant disease relapse remains high. Perioperative immunotherapy may improve outcomes, but mechanistic data supporting the use of neoadjuvant or adjuvant treatment clinically are sparse.Two syngeneic models of oral cavity carcinoma with defined T-cell antigens were treated with programmed death receptor 1 (PD-1) mAb before or after surgical resection of primary tumors, and antigen-specific T-cell responses were explored with functional and in vivo challenge assays.We demonstrated that functional immunodominance developed among T cells targeting multiple independent tumor antigens. T cells specific for subdominant antigens expressed greater levels of PD-1. Neoadjuvant, but not adjuvant, PD-1 immune checkpoint blockade broke immunodominance and induced T-cell responses to dominant and subdominant antigens. Using tumors lacking the immunodominant antigen as a model of antigen escape, neoadjuvant PD-1 immune checkpoint blockade induced effector T-cell immunity against tumor cells lacking immunodominant but retaining subdominant antigen. When combined with complete surgical excision, neoadjuvant PD-1 immune checkpoint blockade led to formation of immunologic memory capable of preventing engraftment of tumors lacking the immunodominant but retaining subdominant antigen.Together, these results implicate PD-1 expression by T cells in the mechanism of functional immunodominance among independent T-cell clones within a progressing tumor and support the use of neoadjuvant PD-1 immune checkpoint blockade in patients with surgically resectable carcinomas.
P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
Authors: N. Altorki, A. Borczuk, A. Saxena, J. Port, B. Stiles, B. Lee, N. Sanfilippo, E. Ko, R. Scheff, B. Pua, J. Gruden, P. Christos, C. Spinelli, J. Gakuria, V. Mittal, T. Mcgraw, S. Formenti
Journal: Journal of Thoracic Oncology (2019)
Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B
Authors: Ekaterina Shiller, Victor Petrov, Pavel Svirin, Vladimir Vdovin, Igor Koltunov, Artyom Bullih, Michael A Maschan, Dmitry Kudlay, Ekaterina Klykova
Journal: Blood (2017)
P1.16-38 Racial Disparities in Long-Term Survival After Surgical Resection in the US
Authors: M. Taylor, M. Smeltzer, N. Faris, M. Ray, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2019)
P1.04-75 Immune-Related Adverse Events and the Neutrophil to Lymphocyte Ratio as Predictors of Clinical Response to Immunotherapy
Authors: H. Powery, L. Raez, D. Johnson, I. Pelt, K. Dumais, G. Domingo, B. Hunis, P. Izquierdo, C. Smith
Journal: Journal of Thoracic Oncology (2019)
Identification of anoctamin 1 (ANO1) as a key driver of esophageal epithelial proliferation in eosinophilic esophagitis
Authors: Simone Vanoni, Chang Zeng, Sahiti Marella, Jazib Uddin, David Wu, Kavisha Arora, Catherine Ptaschinski, Jianwen Que, Taeko Noah, Lisa Waggoner, Artem Barski, Andrey Kartashov, Mark Rochman, Ting Wen, Lisa Martin, Jason Spence, Margaret Collins, Vincent Mukkada, Phillip Putnam, Anjaparavanda Naren, Mirna Chehade, Marc E. Rothenberg, Simon P. Hogan
Journal: Journal of Allergy and Clinical Immunology (2019)
P1.09-31 Clinicopathological Features and Genomic Profiling of Pulmonary Blastoma with High-Grade Fetal Adenocarcinoma Component
Authors: J. Zhao, C. Xiang, P. Wang, P. Guo, J. Zheng, H. Han-Zhang, K. Yu, R. Zhao, J. Zhang, Y. Han
Journal: Journal of Thoracic Oncology (2019)
Somatic Variants: New Kids on the Block in Human Immunogenetics
Authors: L. Van Horebeek, B. Dubois, A. Goris
Journal: Trends in Genetics (2019)

Somatic variants are not inherited but acquired during an individual's lifetime, and individuals are increasingly considered as complex mosaics of genetically distinct cells. Whereas this concept is long-recognized in cancer, this review focuses on the growing role of somatic variants in immune cells in nonmalignant immune-related disorders, such as primary immunodeficiency and autoimmune diseases. Older case reports described somatic variants early in development, leading to large numbers of affected cells and severe phenotypes. Thanks to technological evolution, it is now feasible to detect somatic variants occurring later in life and affecting fewer cells. Hence, only recently is the scale at which somatic variants contribute to monogenic diseases being uncovered and is their contribution to complex diseases being explored systematically.
Application of Computational Biology to Decode Brain Transcriptomes
Authors: Jie Li, Guang-Zhong Wang
Journal: Genomics Proteomics & Bioinformatics (2019)

Abstract The rapid development of high-throughput sequencing technologies has generated massive valuable brain transcriptome atlases, providing great opportunities for systematically investigating gene expression characteristics across various brain regions throughout a series of developmental stages. Recent studies have revealed that the transcriptional architecture is the key to interpreting the molecular mechanisms of brain complexity. However, our knowledge of brain transcriptional characteristics remains very limited. With the immense efforts to generate high-quality brain transcriptome atlases, new computational approaches to analyze these high-dimensional multivariate data are greatly needed. In this review, we summarize some public resources for brain transcriptome atlases and discuss the general computational pipelines that are commonly used in this field, which would aid in making new discoveries in brain development and disorders.
EP1.17-15 Comparison of Long-Term Outcome of Wedge Resection, Anatomical Segmentectomy and Lobectomy in Stage I-II Non-Small Cell Lung Cancer
Authors: K. Sinn, E. Gschwandtner, A. Steindl, S. Taghavi, W. Klepetko, T. Klikovits, M.A. Hoda
Journal: Journal of Thoracic Oncology (2019)
OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis
Authors: B. Ricciuti, A.R. Naqash, B. Henick, D. Rangachari, J. Naidoo, D. Venkatraman, G. Lamberti, G. Recondo, J. Zhang, S. Macherla, S. Baig, P. Walker, K. Sehgal, R. Umeton, L. Sholl, N. Rizvi, D. Costa, M. Awad
Journal: Journal of Thoracic Oncology (2019)
MA14.01 Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations
Authors: W. Peng, J. Li, L. Chang, J. Bai, Y. Zhang, Y. Guan, X. Pu, M. Jiang, J. Cao, B. Chen, X. Xia, X. Yi, J. Zhang, L. Wu
Journal: Journal of Thoracic Oncology (2019)
P1.01-67 Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose
Authors: R. Gentzler, N. Mohindra, S. Jalal, K. Reckamp, R. Hall, N. Hanna, Y.K. Chae, V. Villaflor, M. Koczywas, I. Helenowski, A. Rademaker, J. Patel
Journal: Journal of Thoracic Oncology (2019)
P2.12-09 Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Authors: A. Cummings, J. Goldman, M. Mendenhall, D. Kanamori, A. Nguyen, D. Kim, Z. Wainberg
Journal: Journal of Thoracic Oncology (2019)
P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress
Authors: C. Ocampo, J. Wu, J. Dey, Z. Sun, M. Motwani, A. Reddy, A. Parikh, J. Hay, P. Komarnitsky, B. Bach
Journal: Journal of Thoracic Oncology (2019)
P1.11-04 Utilizing DNA Repair Activity Biomarkers for Lung Cancer Risk Assessment and Early Detection
Authors: T. Paz-Elizur, Y. Leitner-Dagan, K. Meyer, B. Markus, F. Giorgi, M. O’Reilly, H. Kim, Y. Evgy, R. Fluss, L. Freedman, R.C. Rintoul, B. Ponder, Z. Livneh
Journal: Journal of Thoracic Oncology (2019)
EP1.14-30 Cerebrospinal Fluid for Liquid Biopsy in Leptomeningeal Metastases of EGFR-Mutant Non-Small-Cell Lung Cancer – A Case Report
Authors: R. Natal, M. Oliveira, J. Costa, A. Amaral, R. Gomes, L. Ferreira
Journal: Journal of Thoracic Oncology (2019)
MA03.10 Prospective Evaluation of a Prognostic Clinico-Molecular Score (DEMo) to Predict Outcome of Advanced NSCLC Patients Treated with Immunotherapy
Authors: A. Prelaj, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, M. Mensah, G. Galli, A. De Toma, G. Randon, F. Pagani, M. Brambilla, B. Trevisan, M. Ganzinelli, N. Zilembo, F. De Braud, V. Torri, M. Garassino, G. Sozzi, M. Boeri
Journal: Journal of Thoracic Oncology (2019)
P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Authors: E. Nadal, R. Lopez Castro, O. Juan, G. Huidobro, J. De Castro Carpeno, I.G. Sullivan, J. Bosch-Barrera, R. Garcia Campelo, A. Estival, A. Blasco, E. Felip, B. Massuti, M. Guirado, D. Rodriguez-Abreu, M. Domine, M. Simo, V. Navarro, J. Bruna
Journal: Journal of Thoracic Oncology (2019)
Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure
Authors: Cristiana Vitale, Ewa Jankowska, Loreena Hill, Massimo Piepoli, Wolfram Doehner, Stefan D. Anker, Mitja Lainscak, Tiny Jaarsma, Piotr Ponikowski, Giuseppe M.C. Rosano, Petar Seferovic, Andrew J. Coats
Journal: European Journal of Heart Failure (2019)
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Authors: Marc A Suchard, Martijn J Schuemie, Harlan M Krumholz, Seng Chan You, RuiJun Chen, Nicole Pratt, Christian G Reich, Jon Duke, David Madigan, George Hripcsak, Patrick B Ryan
Journal: The Lancet (2019)
Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program
Authors: Paul G Richardson, Joseph H. Antin, Sergio A. Giralt, Robert J. Ryan, Wei Liang, Robin L. Hume, William Martin Tappe, Nancy A. Kernan
Journal: Blood (2017)
Good communication reduces risk of a complaint or claim
Authors: Pallavi Bradshaw
Journal: BMJ (2019)

Chen is right to point out the importance of empathy in being a good doctor.1 Empathy is fundamental to good communication. The Medical Protection Society’s experiences consistently show that patient dissatisfaction with their doctor’s way of communicating fuels most complaints. A 2017 YouGov survey we commissioned of more than 2000 British adults found that 82% …
P2.11-33 Organizational Readiness for Implementation of Lung Cancer Screening in a Veterans Affairs Healthcare System
Authors: L. Spalluto, J. Lewis, C. Callaway-Lane, D. Stolldorf, B. Prusaczyk, H. Limper, C. Audet, T. Vogus, R. Wiener, C. Slatore, D. Yankelevitz, C. Henschke, R. Dittus, P. Massion, C. Lindsell, S. Kripalani, D. Moghanaki, C. Roumie
Journal: Journal of Thoracic Oncology (2019)
EP1.01-40 Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort
Authors: S. Dulal, B. Paudel, A. Shah, P. Neupane, B. Acharya, S. Chapagain, A. Karn, R. Shilpakar, R. Thapa, B. Gautam, O.T. Brustugun, N. Leighl
Journal: Journal of Thoracic Oncology (2019)
MA06.05 Predictive Performance of Quantitative Metabolic Metrics of FDG-PET/CT on Survival and the Effect of Adjuvant Chemotherapy in Lung Cancer
Authors: Y. Makino, Y. Shimada, S. Maehara, H. Masaru, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
Journal: Journal of Thoracic Oncology (2019)
P2.09-03 Prognostic Value of Mutated KRAS in Circulating Tumor DNA Prior to Therapy in Patients with Lung Adenocarcinoma
Authors: S.G.F. Wahl, H.Y. Dai, E.F. Emdal, A.L. Ottestad, E. Richardsen, T.O. Halvorsen, B.H. Gronberg
Journal: Journal of Thoracic Oncology (2019)
Dissecting the genetic basis of comorbid epilepsy phenotypes in neurodevelopmental disorders
Authors: Julie Chow, Matthew Jensen, Hajar Amini, Farhad Hormozdiari, Osnat Penn, Sagiv Shifman, Santhosh Girirajan, Fereydoun Hormozdiari
Journal: Genome Medicine (2019)

Neurodevelopmental disorders (NDDs) such as autism spectrum disorder, intellectual disability, developmental disability, and epilepsy are characterized by abnormal brain development that may affect cognition, learning, behavior, and motor skills. High co-occurrence (comorbidity) of NDDs indicates a shared, underlying biological mechanism. The genetic heterogeneity and overlap observed in NDDs make it difficult to identify the genetic causes of specific clinical symptoms, such as seizures.We present a computational method, MAGI-S, to discover modules or groups of highly connected genes that together potentially perform a similar biological function. MAGI-S integrates protein-protein interaction and co-expression networks to form modules centered around the selection of a single "seed" gene, yielding modules consisting of genes that are highly co-expressed with the seed gene. We aim to dissect the epilepsy phenotype from a general NDD phenotype by providing MAGI-S with high confidence NDD seed genes with varying degrees of association with epilepsy, and we assess the enrichment of de novo mutation, NDD-associated genes, and relevant biological function of constructed modules.The newly identified modules account for the increased rate of de novo non-synonymous mutations in autism, intellectual disability, developmental disability, and epilepsy, and enrichment of copy number variations (CNVs) in developmental disability. We also observed that modules seeded with genes strongly associated with epilepsy tend to have a higher association with epilepsy phenotypes than modules seeded at other neurodevelopmental disorder genes. Modules seeded with genes strongly associated with epilepsy (e.g., SCN1A, GABRA1, and KCNB1) are significantly associated with synaptic transmission, long-term potentiation, and calcium signaling pathways. On the other hand, modules found with seed genes that are not associated or weakly associated with epilepsy are mostly involved with RNA regulation and chromatin remodeling.In summary, our method identifies modules enriched with de novo non-synonymous mutations and can capture specific networks that underlie the epilepsy phenotype and display distinct enrichment in relevant biological processes. MAGI-S is available at https://github.com/jchow32/magi-s .
EP1.01-51 Efficacy Impact of Serum VEGF for Elderly or Poor PS Patients Receiving Anti-PD-1 Antibody with Advanced Non-Small Cell Lung Cancer
Authors: R. Shibaki, S. Murakami, Y. Shinno, Y. Matsumoto, T. Yoshida, Y. Goto, S. Kanda, H. Horinouchi, N. Yamamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2019)
P2.01-60 Analysis of Prognostic Factors According to Performance Status in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Authors: Y. Adachi, A. Tamiya, Y. Taniguchi, T. Enomoto, K. Azuma, S. Kouno, N. Saijo, K. Okishio, S. Atagi
Journal: Journal of Thoracic Oncology (2019)
P2.12-19 Small Cell Lung Cancer (SCLC) Treatment and Survival in Portugal: An IPO-PORTO Analysis from the I-O Optimise Initiative
Authors: M. Soares, L. Antunes, P. Redondo, M. Borges, R. Hermans, D. Patel, C. Chaib, L. Lacoin, A. Juarez-Garcia, M. Daumont, J. Penrod, J. O'Donnell, M. Bento, F. Rocha-Goncalves
Journal: Journal of Thoracic Oncology (2019)